MY PROSTATE SCORE 2.0
A LYNXDX INNOVATION

MyProstateScore 2.0
Next Generation of Prostate Cancer Risk Assessment

MY PROSTATE SCORE 2.0
A LYNXDX INNOVATION

Comprehensive Array of Biomarkers

MPS2 is a urine test that predicts the presence of clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2) by analyzing a comprehensive array of 18 unique gene transcripts. Among the transcripts are the novel gene fusion, T2:ERG, and high-grade specific biomarkers found only in MPS2.

T2:ERG

The most specific biomarker for prostate cancer.

| SCHLAP1 | APOC1 | NKAIN1 | B3GNT6 |

Biomarkers associated with high-grade prostate cancer.

OR51E2	PCAT14	CAMKK2	TFF3
SPON2	PCGEM1	TRGV9	TMSB15A
KLK4	ERG	PCA3	HOXC6

Biomarkers associated with prostate cancer.

KLK3

Reference gene.

Flexible Ordering

Tailor MPS2 to the needs of each patient by ordering:
1. As a biomarker-only test or inclusive of clinical risk factors.
2. With or without a DRE prior to urine collection.

18 Prostate Cancer Biomarkers

T2:ERG
SCHLAP1
APOC1
NKAIN1
B3GNT6
OR51E2
PCAT14
CAMKK2
TFF3

SPON2
PCGEM1
TRGV9
TMSB15A
KLK4
ERG — ExoDx[1] (and SPDEF)
PCA3
HOXC6 — Select mdx[2] (and DLX1)
KLK3

Optional Clinical Risk Factors

Age
PSA
Family History
DRE Finding
African Ancestry
Prostate Volume

Convenient Collection Options

1 At-Home **2** In-Office

Patients can provide their sample in the comfort of their home or during an in-office visit since pre-collection DRE is optional and samples do not require special temperature-controlled packaging.

Best-in-Class Accuracy

The comprehensive array of biomarkers, robust analytical models, and clinical factor flexibility combines to create a test with best-in-class accuracy.

The accuracy of MPS2 is further tailored to specific patient cohorts through separate validation in biopsy naïve men and men with a prior negative biopsy.

When to Use MPS2

MPS2 is indicated for patients without a prior diagnosis of prostate cancer presenting with elevated PSA or an abnormal DRE who are under consideration for an initial or repeat biopsy.

Biopsy Naïve Men

up to 95% NPV

Biopsy naïve men with a low risk MPS2 result have a 92–95% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2).

Men with a Prior Negative Biopsy

up to 99% NPV

Prior negative men with a low risk MPS2 result have a 95–99% probability that their biopsy will be negative for clinically significant prostate cancer (Gleason score ≥7 or Grade Group ≥2).

Risk category: Low or Increasing

Likelihood of Clinically Significant Cancer Grade Group 2 or higher: 0-100%

Easy-to-Interpret Results

MPS2 results are available within 5-7 business days and report the percent likelihood that clinically significant prostate cancer would be detected on biopsy. The cutoff for low risk is dependent on clinical context and takes into consideration prior biopsy status and whether MPS2 is run as a biomarker-only test or inclusive of clinical risk factors.

1 ExoDx is a registered trademark of Exosome Diagnostics, Inc.
2 Select mdx is a registered trademark of MDXHealth S.A.

Reimbursement Support

Lynx Dx is committed to helping patients access our testing services. If your patients need help navigating insurance coverage for MyProstateScore 2.0, our team is here.

Questions or to Get Started

1-888-978-8MPS

or email us at clientservices@lynxdx.com

How to Order MyProstateScore 2.0

At-Home Collection

1. Complete online order form
2. Patient receives kit via mail
3. Patient collects and ships sample
4. Receive results in 5-7 business days

In-Office Collection

1. Complete order form (online or paper)
2. Collect sample (with or without DRE)
3. Package and ship sample
4. Receive results in 5-7 business days

Contact Us

Lynx Dx is committed to providing exceptional service for you and your patients. If you have questions or need assistance, our team is here to help.

Phone: 1-888-978-8677 / 1-888-978-8MPS
Email: clientservices@lynxdx.com | www.lynxdx.com